Morlock Stephen 4
4 · BioPharmX Corp · Filed Nov 27, 2017
Insider Transaction Report
Form 4
BioPharmX Corpbpmx
Morlock Stephen
Director
Transactions
- Purchase
Warrant to purchase common stock
2017-11-24+330,000→ 330,000 totalExercise: $0.25→ Common stock (330,000 underlying) - Purchase
Common stock
2017-11-24$0.15/sh+330,000$49,500→ 873,956 total - Purchase
Warrant to purchase common stock
2017-11-24+330,000→ 330,000 totalExercise: $0.20→ Common stock (330,000 underlying)
Holdings
- 251,071(indirect: By Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03)
Common stock
Footnotes (4)
- [F1]Securities are purchased as a unit, priced at $0.15 per unit, which consists of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock.
- [F2]Mr. Morlock is a co-trustee and co-beneficiary of the Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03
- [F3]This Series A warrant is immediately exercisable and expires on 11/24/2022.
- [F4]This Series B warrant is immediately exercisable and expires on the earlier of (1) the 21st trading day after the Company issues a press release announcing it has entered into a strategic licensing, collaboration, partnership or similar agreement for the commitment to fund its phase 3 trials for BPX01 and (2) the 18 month anniversary of issuance.